UW spinout raises over $5M to target neuromuscular diseases


Myosana's first target is Duchenne muscular dystrophy, a genetic disorder that leads to muscle degeneration.

Previous Mixed-use development with 3 buildings proposed on Main Street in Manayunk
Next Seattle apartment rents up 8% yearly, but increases appear set to slow